Loading
Idecabtagene vicleucel was the first myeloma CAR-T (2021) and is now approved after two prior lines based on KarMMa-3.
Idecabtagene vicleucel is an autologous CAR-T in which a lentiviral vector adds a murine scFv anti-BCMA receptor with 4-1BB costimulation to the patient's T cells, infused once after lymphodepletion. It was the first myeloma CAR-T, approved in 2021 after at least 4 lines on KarMMa (ORR 73%, CR 33%). KarMMa-3 showed PFS 13.3 versus 4.4 months (HR 0.49) against standard regimens in triple-class-exposed patients, leading to approval after at least 2 lines in April 2024; OS was not significantly different unadjusted, and whether crossover-adjusted analyses favouring ide-cel should count remains debated. Cytokine release syndrome occurred in 88% (5% grade 3 or higher) and neurotoxicity in 15%; the REMS was removed in 2025. BMS and 2seventy bio developed it. It is a one-time infusion of engineered immune cells that tripled the time without progression in heavily pretreated myeloma.
Murine scFv anti-BCMA CAR with 4-1BB costimulation; lentiviral. Connects to BCMA.
1.Idecabtagene vicleucel slips into a pocket on BCMA.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Autologous CAR-T covered nationally under NCD 110.24 for FDA-labelled indications at facilities enrolled in the FDA REMS. Inpatient administration is paid under Part A (MS-DRG 018); outpatient administration is a Part B drug. The product itself is bundled into the facility payment. HCPCS Q2055.
Covered with prior authorisation and usually a single-case agreement with a certified treatment centre; many plans restrict to centres of excellence and require documentation of prior lines of therapy.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · CMS NCD 110.24: Chimeric antigen receptor (CAR) T-cell therapy · Medicare.gov: Inpatient hospital care (Part A). Not medical or financial advice; verify with your plan.
Sources: NICE TA1084. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2019-01-03 | Celgene to Bristol Myers Squibb Revlimid, Pomalyst, bb2121 (Abecma), liso-cel (Breyanzi) and the Celgene pipeline | Acquisition | not disclosed | $74bn (plus a contingent value right) | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Relapsed/refractory myeloma after ≥4 lines |
| US | 2024 | After ≥2 lines including IMiD, PI, and anti-CD38 |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Cytokine release syndrome | 88% | 5% |
| Neurotoxicity | 15% | 3% |
| Neutropenia | - | 76% |
KarMMa-3. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (car-t cell therapy) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Idecabtagene vicleucel" OR ABSTRACT:"Idecabtagene vicleucel" OR TITLE:"Abecma" OR ABSTRACT:"Abecma" OR TITLE:"ide-cel" OR ABSTRACT:"ide-cel") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Idecabtagene vicleucel, not a curated reading list.
Shares KarMMa-3, KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, BCMA, CAR-T cell therapy.
Shares KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, BCMA, CAR-T cell therapy, Multiple myeloma.
Shares KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, BCMA, Cytokine release syndrome (CRS), Relapsed or refractory multiple myeloma.
Shares BCMA, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Autologous CAR-T manufacturing, batch by batch, ICANS (neurotoxicity), Cytokine release syndrome (CRS), CAR-T cell therapy.
Shares ICANS (neurotoxicity), BCMA, Cytokine release syndrome (CRS), CAR-T cell therapy.
Shares ICANS (neurotoxicity), BCMA, Cytokine release syndrome (CRS), CAR-T cell therapy.
Shares BCMA expression, Relapsed or refractory multiple myeloma, Multiple myeloma.